Journals / Diagnostic and Interventional Radiology / 2022 / Cilt: 28 - Sayı: 1

Value of contrast-enhanced CT based radiomic machine learning algorithm in differentiating gastrointestinal stromal tumors with KIT exon 11 mutation: a two-center study

Pages
29–38
Publication Date
2022-10-11
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

CONCLUSION The radiomics algorithm could distinguish GISTs with the KIT exon 11 mutation based on CECT images and could potentially be used for selective genetic analysis to support the precision medicine of GISTs.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:PURPOSE Knowing the genetic phenotype of gastrointestinal stromal tumors (GISTs) is essential for patients who receive therapy with tyrosine kinase inhibitors.
📊
Key Findings & Data:The aim of this study was to develop a radiomic algorithm for predicting GISTs with KIT exon 11 mutation.
💡
Conclusion & Impact:CONCLUSION The radiomics algorithm could distinguish GISTs with the KIT exon 11 mutation based on CECT images and could potentially be used for selective genetic analysis to support the precision medicine of GISTs.
🔬Design:Modeling & Simulation
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

PURPOSE Knowing the genetic phenotype of gastrointestinal stromal tumors (GISTs) is essential for patients who receive therapy with tyrosine kinase inhibitors. The aim of this study was to develop a radiomic algorithm for predicting GISTs with KIT exon 11 mutation. METHODS We enrolled 106 patients (80 in the training set, 26 in the validation set) with clinicopathologically confirmed GISTs from two centers. Preoperative and postoperative clinical characteristics were selected and analyzed to construct the clinical model. Arterial phase, venous phase, delayed phase, and tri-phase combined radiomics algorithms were generated from the training set based on contrast-enhanced computed tomography (CE-CT) images. Various radiomics feature selection methods were used, namely least absolute shrinkage and selection operator (LASSO); minimum redundancy maximum relevance (mRMR); and generalized linear model (GLM) as a machine-learning classifier. Independent predictive factors were determined to construct preoperative and postoperative radiomics nomograms by multivariate logistic regression analysis. The performances of the clinical model, radiomics algorithm, and radiomics nomogram in distinguishing GISTs with the KIT exon 11 mutation were evaluated by area under the curve (AUC) of the receiver operating characteristics. RESULTS Of 106 patients who underwent genetic analysis, 61 had the KIT exon 11 mutation. The combined radiomics algorithm was found to be the best prediction model for differentiating the expression status of the KIT exon 11 mutation (AUC = 0.836; 95% confidence interval [CI], 0.640- 0.951) in the validation set. The clinical model, and preoperative and postoperative radiomics nomograms had AUCs of 0.606 (95% CI, 0.397-0.790), 0.715 (95% CI, 0.506-0.873), and 0.679 (95% CI, 0.468-0.847), respectively, with the validation set. CONCLUSION The radiomics algorithm could distinguish GISTs with the KIT exon 11 mutation based on CECT images and could potentially be used for selective genetic analysis to support the precision medicine of GISTs.

🔖

Cite This Article

ZHANG, J., LIU, H., LIU, B., ZHANG, L., SONG, Y., YANG, S., ZHENG, Z., ZHAO, J., HOU, F. (2022). Value of contrast-enhanced CT based radiomic machine learning algorithm in differentiating gastrointestinal stromal tumors with KIT exon 11 mutation: a two-center study. Diagnostic and Interventional Radiology, Cilt: 28 - Sayı: 1, 29–38. https://ajindex.com/articles/487220

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol. 2003
  2. 21(23):4342-4349. [Crossref] 2. Randall RL, Benjamin RS, Boles S, et al. Soft Tissue Sarcoma, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2018
  3. 16(5):536-563. [Crossref] 3. Edmonson JH, Marks RS, Buckner JC, Mahoney MR. Contrast of response to dacarbazine, mitomycin, doxorubicin, and cisplatin (DMAP) plus GM-CSF between patients with advanced malignant gastrointestinal stromal tumors and patients with other advanced l eiomyosarcomas. Cancer Invest. 2002
  4. 20(5-6):605-612. [Crossref] 4. Oppelt PJ, Hirbe AC, Van Tine BA. Gastrointestinal stromal tumors (GISTs): point mutations matter in management, a review. J Gastrointest Oncol. 2017
  5. 8(3):466-473. [Crossref] 5. Heinrich MC, Owzar K, Corless CL, et al. Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol. 2008
  6. 26(33):5360-5367. [Crossref] 6. Chen P, Zong L, Zhao W, Shi L. Efficacy evaluation of imatinib treatment in patients with gastrointestinal stromal tumors: a meta-analysis. World J Gastroenterol. 2010
  7. 16(33):4227-4232. [Crossref] 7. Corless CL, Ballman KV, Antonescu CR, et al. Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial. J Clin Oncol. 2014
  8. 32(15):1563-1570. [Crossref] 8. Kim GH, Ahn JY, Gong CS, et al. Efficacy of Endoscopic Ultrasound-Guided Fine-Needle Biopsy in Gastric Subepithelial Tumors Located in the Cardia. Dig Dis Sci. 2019
  9. [Crossref] 9. Chen T, Xu L, Dong X, et al. The roles of CT and EUS in the preoperative evaluation of gastric gastrointestinal stromal tumors larger than 2 cm. Eur Radiol. 2019
  10. 29(5):2481-2489. [Crossref] 10. Li J, Ye Y, Wang J, et al. Chinese consensus guidelines for diagnosis and management of gastrointestinal stromal tumor. Chin J Cancer Res. 2017
  11. 29(4):281-293. [Crossref] 11. Xu F, Ma X, Wang Y, et al. CT texture analysis can be a potential tool to differentiate gastrointestinal stromal tumors without KIT exon 11 mutation. Eur J Radiol. 2018
  12. [Crossref] 12. Choi H. Response evaluation of gastrointestinal stromal tumors. Oncologi